Lv6
3160 积分 2022-09-01 加入
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
9天前
已完结
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
11天前
已完结
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation
1个月前
已完结
Selective Targeting of STAT6: Recent Advances and Future Perspectives
1个月前
已完结
An updated patent review of STAT6 inhibitors and modulators (2020 – present)
1个月前
已完结
A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles
2个月前
已完结
Cytochrome P450 Induction
2个月前
已关闭
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N -[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile
2个月前
已完结
A Decade of FDA-Approved Pharmacophore-Based Small Molecules: Advances in Medicinal Chemistry from 2014 to 2024
3个月前
已完结